Literature DB >> 2060184

Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice.

G N Van Muijen1, L M Cornelissen, C F Jansen, C G Figdor, J P Johnson, E B Bröcker, D J Ruiter.   

Abstract

In order to study differences in antigen expression related to the different stages of the process of metastasis of human melanoma cell lines, we determined the expression pattern of a series of well-characterized genes in a set of human melanoma cell lines with different metastatic behavior in nude mice. This set included non-metastatic (IF6, 530), sporadically metastatic (M14, Mel 57), and frequently metastatic (BLM, MV3) cell lines after subcutaneous inoculation. To study the phenotype of these cell lines both the cultured cells and representative samples of local tumors at the inoculation site and their metastases in the lungs were immunostained with a panel of monoclonal antibodies directed against melanocytic differentiation or progression antigens. Although most cell lines (IF6, 530, M14 and Mel 57) showed HLA-DR expression in vitro, these antigens were lacking in all xenografted lesions studied with exception of the 530 cell line. 530 Xenografts, however, showed a dramatic down-regulation of HLA-DR compared with the cell line in vitro. The same phenomenon was seen with respect to ICAM-1 expression. The expression of all other antigens studied in xenografts, both in subcutaneous tumors and in lung lesions, was in general comparable to that in the melanoma cell lines in vitro, with exception of the 530 cell line. In all melanoma cell lines except 530 the degree of intra- and interlesional heterogeneity regarding the expression of all antigens studied was limited. Remarkably, comparison of the immunophenotype of the frequently metastasizing (BLM, MV3) and the sporadically (M14, Mel 57) or non-metastasizing (IF6, 530) cell lines showed that the two frequently metastasizing cell lines had marked expression of the progression antigens VLA-2 and epidermal growth factor receptor, and lack of expression of the differentiation antigen NKI-beteb. These findings warrant further studies on the role of these antigens in the process of metastasis of human melanoma cells in nude mice.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2060184     DOI: 10.1007/bf01753729

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  34 in total

1.  Enzyme-labeled antibodies: preparation and application for the localization of antigens.

Authors:  P K Nakane; G B Pierce
Journal:  J Histochem Cytochem       Date:  1966-12       Impact factor: 2.479

2.  Characterization of melanoma-associated surface antigens involved in the adhesion and motility of human melanoma cells.

Authors:  J E de Vries; G D Keizer; A A te Velde; A Voordouw; D Ruiter; P Rümke; H Spits; C G Figdor
Journal:  Int J Cancer       Date:  1986-10-15       Impact factor: 7.396

3.  Level of HLA antigens in locoregional metastases and clinical course of the disease in patients with melanoma.

Authors:  S G van Duinen; D J Ruiter; E B Broecker; E A van der Velde; C Sorg; K Welvaart; S Ferrone
Journal:  Cancer Res       Date:  1988-02-15       Impact factor: 12.701

4.  Gene products of the HLA-D region in normal and malignant tissues of nonlymphoid origin.

Authors:  P Natali; A Bigotti; R Cavalieri; M R Nicotra; R Tecce; D Manfredi; Y X Chen; L M Nadler; S Ferrone
Journal:  Hum Immunol       Date:  1986-02       Impact factor: 2.850

5.  Interferon gamma regulates HLA-D expression on solid tumors in vivo.

Authors:  F R Balkwill; M H Stevens; D B Griffin; J A Thomas; J G Bodmer
Journal:  Eur J Cancer Clin Oncol       Date:  1987-01

6.  Antigenic profile of tumor progression stages in human melanocytic nevi and melanomas.

Authors:  D E Elder; U Rodeck; J Thurin; F Cardillo; W H Clark; R Stewart; M Herlyn
Journal:  Cancer Res       Date:  1989-09-15       Impact factor: 12.701

7.  Expression of metastatic potential of allogenic and xenogeneic neoplasms in young nude mice.

Authors:  N Hanna; I J Fidler
Journal:  Cancer Res       Date:  1981-02       Impact factor: 12.701

8.  Phenotypic dynamics of tumor progression in human malignant melanoma.

Authors:  E B Bröcker; L Suter; J Brüggen; D J Ruiter; E Macher; C Sorg
Journal:  Int J Cancer       Date:  1985-07-15       Impact factor: 7.396

9.  Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin.

Authors:  J P Johnson; M Demmer-Dieckmann; T Meo; M R Hadam; G Riethmüller
Journal:  Eur J Immunol       Date:  1981-10       Impact factor: 5.532

10.  Supernatants of human leukocytes contain mediator, different from interferon gamma, which induces expression of MHC class II antigens.

Authors:  G Groenewegen; M de Ley; G M Jeunhomme; W A Buurman
Journal:  J Exp Med       Date:  1986-07-01       Impact factor: 14.307

View more
  23 in total

1.  Melanocyte lineage-specific antigens recognized by monoclonal antibodies NKI-beteb, HMB-50, and HMB-45 are encoded by a single cDNA.

Authors:  G J Adema; A J de Boer; R van 't Hullenaar; M Denijn; D J Ruiter; A M Vogel; C G Figdor
Journal:  Am J Pathol       Date:  1993-12       Impact factor: 4.307

2.  MEMD, a new cell adhesion molecule in metastasizing human melanoma cell lines, is identical to ALCAM (activated leukocyte cell adhesion molecule).

Authors:  W G Degen; L C van Kempen; E G Gijzen; J J van Groningen; Y van Kooyk; H P Bloemers; G W Swart
Journal:  Am J Pathol       Date:  1998-03       Impact factor: 4.307

3.  Nuclear heparanase-1 activity suppresses melanoma progression via its DNA-binding affinity.

Authors:  Y Yang; C Gorzelanny; A T Bauer; N Halter; D Komljenovic; T Bäuerle; L Borsig; M Roblek; S W Schneider
Journal:  Oncogene       Date:  2015-03-09       Impact factor: 9.867

4.  Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes.

Authors:  I C Le Poole; F M van den Berg; R M van den Wijngaard; D A Galloway; P J van Amstel; A A Buffing; H L Smits; W Westerhof; P K Das
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997-01       Impact factor: 2.416

5.  Analysis of the tumor vasculature and metastatic behavior of xenografts of human melanoma cell lines transfected with vascular permeability factor.

Authors:  A J Pötgens; M C van Altena; N H Lubsen; D J Ruiter; R M de Waal
Journal:  Am J Pathol       Date:  1996-04       Impact factor: 4.307

6.  Immortalization of human melanocytes does not alter the de novo properties of nitric oxide to induce cell detachment from extracellular matrix components via cGMP.

Authors:  Krassimira Ivanova; Britta Lambers; Rene van den Wijngaard; I Caroline Le Poole; Olga Grigorieva; Rupert Gerzer; Pranab K Das
Journal:  In Vitro Cell Dev Biol Anim       Date:  2008-07-02       Impact factor: 2.416

7.  Using In Vitro Live-cell Imaging to Explore Chemotherapeutics Delivered by Lipid-based Nanoparticles.

Authors:  Ann L B Seynhaeve; Timo L M Ten Hagen
Journal:  J Vis Exp       Date:  2017-11-01       Impact factor: 1.355

8.  Cultivation-dependent plasticity of melanoma phenotype.

Authors:  Ondřej Kodet; Barbora Dvořánková; Eliška Krejčí; Pavol Szabo; Petr Dvořák; Jiří Štork; Ivana Krajsová; Pavel Dundr; Karel Smetana; Lukáš Lacina
Journal:  Tumour Biol       Date:  2013-06-12

9.  Vascular permeability factor expression influences tumor angiogenesis in human melanoma lines xenografted to nude mice.

Authors:  A J Pötgens; N H Lubsen; M C van Altena; J G Schoenmakers; D J Ruiter; R M de Waal
Journal:  Am J Pathol       Date:  1995-01       Impact factor: 4.307

10.  Loss of microRNA-200a and c, and microRNA-203 expression at the invasive front of primary cutaneous melanoma is associated with increased thickness and disease progression.

Authors:  Léon C van Kempen; Karin van den Hurk; Vladimir Lazar; Stefan Michiels; Véronique Winnepenninckx; Marguerite Stas; Alan Spatz; Joost J van den Oord
Journal:  Virchows Arch       Date:  2012-09-06       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.